Polycystic Ovary Syndrome (PCOS), a common hormonal condition impacting 1 in 8 women, has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change, published in The Lancet after 14 years of collaboration, aims to improve understanding and care by better reflecting the condition's broad metabolic, reproductive, and overall health implications.
A significant change in the medical world has occurred: Polycystic Ovary Syndrome (PCOS), a hormonal condition prevalent in 1 in 8 women globally, is now officially called Polyendocrine Metabolic Ovarian Syndrome (PMOS). This renaming, the result of 14 years of expert and patient collaboration, was announced in The Lancet and aims to enhance understanding and improve care for those affected. PMOS is characterized by fluctuating hormones that can impact weight, metabolic and mental health, the reproductive system, and skin. It is closely linked to metabolic syndrome, which heightens the risk of Type 2 diabetes, heart disease, and stroke. While the exact cause remains unknown, genetics and obesity are believed to play roles. Symptoms of PMOS vary, making diagnosis challenging. Key indicators include irregular menstrual cycles and excessive androgen production, leading to issues like acne, hair growth, or thinning. Ovarian follicles may also be present, though these are not abnormal cysts. For teenagers, diagnosis typically requires both irregular periods and signs of high androgens, such as elevated blood levels or severe acne. PMOS is a leading cause of female infertility due to infrequent ovulation and can increase the risk of pregnancy complications like gestational diabetes or preterm birth, though most individuals can still successfully carry a pregnancy. Treatment primarily focuses on lifestyle modifications, including a healthy diet, regular exercise, and adequate sleep, to address insulin resistance which often leads to high testosterone levels and subsequent symptoms. Other treatments include insulin-sensitizing medications like Metformin, androgen blockers, and hormonal birth control. Experts stress that management should be individualized, tailored to specific symptoms and patient goals, such as fertility or symptom management. The name change is being disseminated among medical professionals, with hopes of raising greater awareness about the condition's multifaceted reality and fostering more effective patient support.
